BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 10551332)

  • 1. Cytokines required for induction of histocompatibility leukocyte antigen-class I-restricted and tumor-specific cytotoxic T lymphocytes by a SART1-derived peptide.
    Matsunaga K; Nakao M; Masuoka K; Inoue Y; Gouhara R; Imaizumi T; Nishizaka S; Itoh K
    Jpn J Cancer Res; 1999 Sep; 90(9):1007-15. PubMed ID: 10551332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytotoxic T cell induction against human malignant melanoma cells using HLA-A24-restricted melanoma peptide cocktail.
    Akiyama Y; Maruyama K; Nara N; Mochizuki T; Yamamoto A; Yamazaki N; Kawashima I; Nukaya I; Takesako K; Yamaguchi K
    Anticancer Res; 2004; 24(2B):571-7. PubMed ID: 15160996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a SART-1-derived peptide capable of inducing HLA-A24-restricted and tumor-specific cytotoxic T lymphocytes.
    Kikuchi M; Nakao M; Inoue Y; Matsunaga K; Shichijo S; Yamana H; Itoh K
    Int J Cancer; 1999 May; 81(3):459-66. PubMed ID: 10209962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed Death-Ligand 1 on Antigen-presenting Cells Facilitates the Induction of Antigen-specific Cytotoxic T Lymphocytes: Application to Adoptive T-Cell Immunotherapy.
    Goto T; Nishida T; Takagi E; Miyao K; Koyama D; Sakemura R; Hanajiri R; Watanabe K; Imahashi N; Terakura S; Murata M; Kiyoi H
    J Immunother; 2016 Oct; 39(8):306-15. PubMed ID: 27548033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Host-oriented peptide evaluation using whole blood assay for generating antigen-specific cytotoxic T lymphocytes.
    Kawabuchi Y; Yamaguchi Y; Ohshita A; Minami K; Toge T
    Anticancer Res; 2004; 24(2C):1193-200. PubMed ID: 15154646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient induction of specific cytotoxic T lymphocytes to tumor rejection peptide using functional matured 2 day-cultured dendritic cells derived from human monocytes.
    Tanaka F; Yamaguchi H; Haraguchi N; Mashino K; Ohta M; Inoue H; Mori M
    Int J Oncol; 2006 Nov; 29(5):1263-8. PubMed ID: 17016660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.
    Horiguchi Y; Nukaya I; Okazawa K; Kawashima I; Fikes J; Sette A; Tachibana M; Takesako K; Murai M
    Clin Cancer Res; 2002 Dec; 8(12):3885-92. PubMed ID: 12473604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A24-restricted peptide of carcinoembryonic antigen.
    Itoh T; Ueda Y; Kawashima I; Nukaya I; Fujiwara H; Fuji N; Yamashita T; Yoshimura T; Okugawa K; Iwasaki T; Ideno M; Takesako K; Mitsuhashi M; Orita K; Yamagishi H
    Cancer Immunol Immunother; 2002 Apr; 51(2):99-106. PubMed ID: 11904734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the tumor-rejection antigen SART1 in brain tumors.
    Imaizumi T; Kuramoto T; Matsunaga K; Shichijo S; Yutani S; Shigemori M; Oizumi K; Itoh K
    Int J Cancer; 1999 Dec; 83(6):760-4. PubMed ID: 10597192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction of antigen-specific cytotoxic T lymphocytes by using monocyte-derived DCs transfected with in vitro-transcribed WT1 or SART1 mRNA.
    Narita M; Tochiki N; Saitoh A; Watanabe N; Kaji M; Satoh N; Yamahira A; Nakamura T; Masuko M; Furukawa T; Toba K; Fuse I; Aizawa Y; Takahashi M
    Med Oncol; 2009 Dec; 26(4):429-36. PubMed ID: 19058036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of a human leukocyte antigen-A24-restricted antitumor cell with the use of SART-1 peptide and dendritic cells in patients with malignant brain tumors.
    Yoshida S; Tanaka R
    J Lab Clin Med; 2004 Oct; 144(4):201-7. PubMed ID: 15514588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell receptor Vbeta gene usage by T cells reactive with the tumor-rejection antigen SART-1 in oral squamous cell carcinoma.
    Kumamaru W; Nakamura S; Kadena T; Yamada A; Kawamura E; Sasaki M; Ohyama Y; Toyoshima T; Hayashida JN; Itoh K; Shirasuna K
    Int J Cancer; 2004 Feb; 108(5):686-95. PubMed ID: 14696095
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A wild-type sequence p53 peptide presented by HLA-A24 induces cytotoxic T lymphocytes that recognize squamous cell carcinomas of the head and neck.
    Eura M; Chikamatsu K; Katsura F; Obata A; Sobao Y; Takiguchi M; Song Y; Appella E; Whiteside TL; DeLeo AB
    Clin Cancer Res; 2000 Mar; 6(3):979-86. PubMed ID: 10741724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of HLA-A24-restricted CTL epitope from cancer-testis antigen, NY-ESO-1, and induction of a specific antitumor immune response.
    Yamaguchi H; Tanaka F; Ohta M; Inoue H; Mori M
    Clin Cancer Res; 2004 Feb; 10(3):890-6. PubMed ID: 14871964
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of specific CTL by MAGE-3/CEA peptide-pulsed dendritic cells from HLA-A2/A24(+) gastrointestinal cancer patients.
    Hao X; Shao Y; Ren X; Liu H; Xu Q; Li H; Zhang P; An X; Ren B
    J Cancer Res Clin Oncol; 2002 Sep; 128(9):507-15. PubMed ID: 12242516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of the SART1 tumor rejection antigen in renal cell carcinoma.
    Shintaku I; Kawagoe N; Yutani S; Hoshi S; Orikasa S; Yoshizumi O; Itoh K
    Urol Res; 2000 Jun; 28(3):178-84. PubMed ID: 10929426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24.
    Tanaka F; Fujie T; Tahara K; Mori M; Takesako K; Sette A; Celis E; Akiyoshi T
    Cancer Res; 1997 Oct; 57(20):4465-8. PubMed ID: 9377553
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a MAGE-2-encoded human leukocyte antigen-A24-binding synthetic peptide that induces specific antitumor cytotoxic T lymphocytes.
    Tahara K; Takesako K; Sette A; Celis E; Kitano S; Akiyoshi T
    Clin Cancer Res; 1999 Aug; 5(8):2236-41. PubMed ID: 10473111
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of hepatitis C virus-specific cytotoxic T lymphocytes from healthy individuals with peptide-pulsed dendritic cells.
    Ito A; Kanto T; Kuzushita N; Tatsumi T; Sugimoto Y; Miyagi T; Takehara T; Katayama K; Mochizuki K; Hiramatsu N; Kasahara A; Yoshiya I; Sasaki Y; Hori M; Hayashi N
    J Gastroenterol Hepatol; 2001 Mar; 16(3):309-16. PubMed ID: 11339423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.